Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

#1759

Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.

Aim(s): A new “ready-to-use” 68Ga-DOTATOC formulation for injection aims to simplify the synthesis of the final radiotracer.

Materials and methods: This phase I/II multicentre, open label study assessed the safety and tolerability of a single dose of 68Ga-DOTATOC (prepared on the day of the scan; product stability: 4 hours) 2 MBq/kg ± 10% (range 100-200 MBq) in patients with biopsy-proven grade 1-2 GEP-NETs. PET-CT imaging was performed 40-60 minutes post injection. Patients were followed-up for 28 days for safety/ tolerability assessment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Manoharan P

Authors: Manoharan P, Navalkissoor S, Lamarca A, Calero J, Chan P,

Keywords: SomaKit, DOTATOC, GEP-NET,